Living with Cystic Fibrosis: Jordan's Story

Lessons Jordan Learned Living with Cystic Fibrosis (CF) Lessons Jordan Learned Living with Cystic Fibrosis (CF)

Every CF patient has a story. Jordan, Brian, and Emily have shared theirs to inspire other patients.

Living with cystic fibrosis (CF) can be tough, but you're not alone! Many patients have overcome challenges and realized the importance of prioritizing their treatments.

Learn from their experience and see how their everyday lives have changed for the better.

I did not always understand the importance of sustaining my daily CF care

How are lungs affected by CF different?

For people living with CF, the mucus in the lungs is thicker than normal, and it becomes a source of inflammation, infection, and decreased lung function. Learn more ›

Though you may not see or feel the signs and symptoms of CF right away, the disease is still present.

When I was in college, doing Pulmozyme and my other treatments was not a high priority for me

Selected Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients. Please see the continued Important Safety Information below, and see the Pulmozyme full Prescribing Information for additional Important Safety Information.

Pulmozyme is the only FDA-approved mucolytic that, in laboratory studies, was shown to make mucus thinner and looser to help make it easier to cough up.

Why is Pulmozyme an important part of my cystic fibrosis treatment regimen?

As seen in laboratory studies, Pulmozyme has a distinct role among medicines to help make mucus thinner and looser by cutting the extracellular DNA that makes mucus thick and sticky. Your doctor will prescribe other medicines to take, in addition to Pulmozyme. Learn more ›
Once my perspective changed, I decided to do my treatments and make that a priority

Talk to your CF Care Team about how to come up with a treatment routine that works best for you.

Should I continue using Pulmozyme even when I can't feel it?

It is important to take Pulmozyme as your doctor has prescribed. Pulmozyme has a distinct role in the fight against CF. One of the causes of thickened mucus in the lungs is extracellular DNA. As seen in laboratory studies, Pulmozyme uniquely cuts apart extracellular DNA by acting like an enzyme naturally found in the lungs. Cutting up extracellular DNA can help make mucus thinner and looser, which can make it easier to clear your lungs. In a clinical study of patients over 5 years of age with forced vital capacity (FVC) greater than 40% of predicted, Pulmozyme, when taken once-daily or twice-daily, was shown to improve lung function in most patients. Even when you can't feel Pulmozyme working to fight CF, it is. Learn more ›
Watch more CF Life Lessons

Indication and Important Safety Information

Indication and Usage

Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

For additional Important Safety Information, please click here for the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF Care Team.